Beach Energy is a gas-focused Australian producer supplying the domestic east coast market, with most output coming from the Cooper, Otway and Perth basins. The key growth driver is the Waitsia Gas Project, which could lift production and cash flow as it ramps up. The stock offers a high fully franked dividend but remains sensitive to energy prices and project execution.
Paladin Energy is a leveraged uranium producer centred on the restarted Langer Heinrich mine in Namibia. Its earnings are highly sensitive to uranium prices, making the stock a direct play on the nuclear fuel cycle. Future growth could come from the large Patterson Lake South project in Canada.
Yancoal Australia is largely a pure play on global coal prices, with profits rising and falling almost directly with commodity cycles. The company has dramatically strengthened its balance sheet, eliminating over $3bn of debt and building more than $2bn in cash, giving it one of the most conservative capital structures among coal producers. Even after coal prices normalised, low operating costs allow the business to remain profitable with solid cash flow and sustainable production levels.
Immutep is a Sydney-based clinical-stage biotechnology company focused on immunotherapy, specifically targeting the LAG-3 immune pathway. The company is dual-listed on the ASX and NASDAQ, giving it access to both Australian and US capital markets. It does not yet generate commercial product revenue and remains dependent on capital markets and partnerships to fund its development programs, making it a milestone-driven investment rather than a revenue-backed operating business.
Monadelphous Group is a high-quality, cycle-exposed engineering contractor leveraged to Australian resources and energy capex. Strong cash generation, a net cash balance sheet and disciplined contract selection underpin its reputation and dividend capacity. Long-standing Tier 1 client relationships support earnings resilience across mining, LNG and infrastructure projects. However, the current valuation suggests much of the favourable operating outlook is already priced in.
If you bought Neuren Pharmaceuticals (ASX: NEU) near its peak, the recent volatility has been uncomfortable. Despite having its first approved drug for a rare paediatric disorder, growing royalty income and a promising pipeline, the share price has repeatedly rallied and retraced over the past two years. The key question now is whether NEU has already formed a durable bottom — or if another leg down could still test investor conviction.
